In vivo retention and bioactivity of IL-1ra microspheres in the rat intervertebral disc: a preliminary investigation
© Gorth et al.; licensee Springer. 2014
Received: 27 August 2014
Accepted: 14 November 2014
Published: 21 November 2014
Inflammatory cytokines such as interleukin-1 beta (IL-1β) contribute to the progression of intervertebral disc degeneration. Previously we demonstrated, in vitro, that by delivering interleukin-1 receptor antagonist (IL-1ra) from poly(lactic co-glycolic acid) (PLGA) microspheres, we could attenuate the degradative effects of IL-1β on the nucleus pulposus (NP) for up to 20 days. The objective of this study was to undertake a preliminary investigation into whether microspheres could be successfully delivered to and retained in the disc in vivo, and whether IL-1ra released from those microspheres remained biologically active. For retention studies, fluorescently-labeled microspheres were delivered to the NPs of rat caudal discs. Rats were sacrificed at time points up to 56 days, and microspheres were localized using fluorescent microscopy. To investigate whether IL-1ra microspheres could effectively inhibit the effects of IL-1β in vivo, four disc levels were allocated to the following treatment groups: intact; saline; IL-1β; or IL-1β + IL-1ra microspheres. Rats were sacrificed after seven days and NP glycosaminoglycan content was measured.
Microspheres were visible in the disc at all time points up to 28 days, and localized to the NP, the annulus fibrosus (AF), or both. Glycosaminoglycan content for discs injected with IL-1β alone was significantly lower than for intact controls. For discs injected with IL-1β along with IL-1ra microspheres, glycosaminoglycan content was not significantly different from intact controls.
Microspheres can successfully be delivered to the disc in vivo and retained for a clinically relevant time frame. IL-1ra released from microspheres can effectively prevent IL-1β-induced NP glycosaminoglycan loss in vivo.
KeywordsIntervertebral disc degeneration Inflammation Interleukin-1 receptor antagonist PLGA microspheres Rat In vivo
Intervertebral disc degeneration is a cascade beginning with changes to the local cellular microenvironment and progressing over years to structural breakdown and functional impairment ,. Changes to the central nucleus pulposus (NP) are implicated in the early stages of disc degeneration, where decreasing proteoglycan content and an associated reduction in hydrostatic pressure impair the ability of the disc to evenly distribute and transfer compressive loads between the vertebrae . Inflammation plays a key role in the progression of disc degeneration. Interleukin-1 beta (IL-1β), in particular, is more highly expressed in the degenerate NP than in the healthy NP . Elevated IL-1β induces catabolic protease activity, which degrades the disc extracellular matrix and contributes to structural failure . Interleukin-1 receptor antagonist (IL-1ra) is an endogenous inhibitor of IL-1β, where it acts by competitively blocking the binding of IL-1β to receptors on IL-1 responsive cells . While IL-1β is upregulated with disc degeneration, there is no concomitant upregulation of IL-1ra , resulting in an imbalance between catabolic and anabolic signaling. In our previous in vitro work, we demonstrated that soluble IL-1ra effectively inhibited the degradative effects of IL-1β on NP cells . Further, by delivering IL-1ra from poly(lactic-co-glycolic acid) (PLGA) microspheres, inhibition could be maintained for up to 20 days . Key advantages of PLGA microspheres for drug delivery include that they are biodegradable and biocompatible, already FDA approved for other clinical indications, and most importantly, can be easily tuned to alter degradation and protein release kinetics ,.
The objective of this study was to advance this encouraging in vitro work to towards clinical translation, by undertaking a preliminary in vivo study to demonstrate, firstly, that PLGA microspheres could be delivered to the disc and retained for a clinically relevant time frame in vivo; and, secondly, that IL-1ra delivered from these microspheres maintained bioactivity in the in vivo space.
Materials and methods
PLGA microspheres were fabricated as described previously, using the water/oil/water double emulsion technique ,. As in our previous work, we used the pharmaceutical form of IL-1ra, anakinra (Amgen, Thousand Oaks, CA). The initial water/oil emulsion was formed by combining 225μL of IL-1ra (0.15 g/ml) with 1 ml of 75:25 PLGA (0.1 g/ml) (Durect Corporation, Pelham, AL). For fluorescent microsphere studies, the PLGA was supplemented with 3 mg/ml coumarin-6 (Sigma Aldrich; λemission =505 nm; λabsorption =444 nm), and saline was substituted for IL-1ra. Fabricated microspheres were lyophilized until required for surgeries, and sterilized via exposure to ultraviolet light for 10 min prior to injection. The release profile of IL-1ra from these microspheres was described previously, and is characterized by an initial burst release, decreasing to an approximately linear and sustained release over the initial 10 days. In vitro, bioactive IL-1ra continues to be released for up to 20 days .
In vivo microsphere retention study
In vivo bioactivity study
Next, we performed a study to confirm the in vivo bioactivity of IL-1ra microspheres delivered to the rat NP. Four caudal disc levels per animal were utilized (C7-8, C8-9, C9-10 and C10-11), and randomly allocated to one of four study groups: intact (non-injected) controls; sham (vehicle only) injection; IL-1β injection; or IL-1β + IL-1ra microspheres (20 mg/ml) injection. The study was performed for each of two IL-1β doses: 100 ng and 500 ng (each n = 4 animals). All injection volumes were 1.5 μl with sterile saline as the vehicle, delivered using modified 33-gauge needles. Surgeries were performed as described above. All animals were euthanized 7 days post-surgery. Following euthanasia, spine segments containing injected or control discs were isolated, and NP regions analyzed for GAG content. To overcome the challenges associated with accurate determination of GAG content in very small tissue specimens, we developed a dissection technique to accurately isolate NP samples of known volume. Spine segments were snap frozen and mounted in a cryostat microtome. Sections of vertebral bone were progressively removed until the transverse face of the disc was exposed. Four 100 μm-thick sections of disc were then cut and transferred, frozen, to a glass microscope slide. A 1 mm biopsy punch was then used to isolate the NP from the AF. Isolated NP samples were then digested in papain and assayed to determine total sulfated GAG content (expressed as absolute GAG per sample) using the dimethylmethylene blue technique . Differences in GAG content between groups were established using ANOVAs followed by post-hoc, pairwise Tukey’s tests. Results were expressed as mean ± standard deviation, with significance defined as p < 0.05.
In vivo retention of microspheres
To determine whether microspheres could be successfully delivered to the rat disc and retained for a clinically relevant time frame, fluorescent microspheres were injected into rat caudal discs, and their presence or absence and localization (AF or NP) investigated at six post-surgical timepoints up to 8 weeks. Fluorescence microscopy confirmed the presence of microspheres in all discs and at all time points up to 28 days post-surgery. In discs where microspheres were present, their localization varied between the AF only (63% of discs, Figures 1C-E), the NP only (13% of discs, Figures 1F-H), or both the NP and the AF (25% of discs). There was no apparent association between time point and location of microspheres in the disc. Cryostat sections were also examined for evidence of microsphere leakage along the injection track, but no such leakage was observed.
In vivo bioactivity of IL-1ra microspheres
Discussion and conclusions
IL-1ra has successfully been used clinically for the treatment of rheumatoid arthritis for a number of years , and has recently been investigated as a potential treatment for osteoarthritis . In previous work we demonstrated that soluble IL-1ra can effectively inhibit the degradative effects of IL-1β on the NP at the mechanical, compositional and molecular levels . Another study showed that IL-1ra delivered both directly in solution and by gene therapy inhibited mRNA expression and activity of catabolic enzymes upregulated by IL-1β in disc tissue explants . Further, IL-1ra knockout mice exhibit degenerative changes consistent with human disc degeneration .
The avascular nature of the disc, along with the short half-life and required high therapeutic concentrations of IL-1ra , suggest that in vivo, systemic delivery for treatment of disc degeneration is unlikely to be successful. Repeated intradiscal injections of IL-1ra that would be necessary to sustain high local concentrations, are impractical and may induce further degenerative changes via structural damage to the AF resulting from repetitive delivery. Therefore, to enhance the therapeutic efficacy of IL-1ra for treating disc degeneration, we developed a sustained release delivery vehicle for IL-1ra. Using biodegradable PLGA microspheres, we demonstrated previously that, in vitro, we could inhibit the degradative effects of IL-1β on the NP for up to 20 days. Building on these results, in this study we demonstrated that PLGA microspheres can be delivered to the disc in vivo and be retained for up to 28 days. Importantly, retention time in the disc (analogous to the time it takes for microspheres to fully degrade), is longer than the time period over which microspheres continue to release active IL-1ra at therapeutic concentrations . In our microsphere retention study, variability was apparent with respect to the location of microspheres in the disc (NP, AF or both). One possible explanation for this is that, with time, microspheres diffuse away from the NP towards the AF where they are caught in the dense, fibrocartilaginous lamellae. However, as there was no apparent association between time point and location of microspheres in the disc, a more likely explanation may have been minor inconsistencies in injection location. We hypothesize that active IL-1ra released from microspheres is likely to diffuse throughout the entire disc structure, irrespective of the location of microspheres. The results of the in vivo bioactivity study reported here support this contention: IL-1ra microspheres successfully inhibited NP GAG loss induced by IL-1β.
This study represents a preliminary investigation into the in vivo efficacy of using anti-inflammatory microspheres in the intervertebral disc, and is not without limitations. Additional study groups should be investigated as part of future work, such as injection of blank (non-IL-1ra loaded) microspheres, specifically to determine if acidic microsphere degradation products exert any inflammatory effect. Clearance of these degradation products must occur via passive diffusion to vasculature outside the NP. Our previous in vitro work suggests that any such effects are likely quite mild . Future studies should also confirm that these microspheres are active for long periods in vivo, in the presence of chronic inflammation, and are more effective under such circumstances than a single, bolus injection of IL-1ra. The small sample size was an addition limitation of this study, although it was sufficient to detect significant changes in GAG content.
Attenuation of inflammation in the degenerate disc is only one component of a potential biological therapy for disc degeneration. A stem cell-based component may be required to potentiate tissue regeneration. In addition to preventing further degenerative changes, IL-1ra microspheres may foster a microenvironment that is anti-inflammatory and more conducive to stem cell survival, differentiation and biosynthesis . Pursuant to the encouraging findings reported here, we are now designing combined anti-inflammatory and stem cell-based therapeutics for disc regeneration and evaluating their efficacy in large animal models.
Ethics board approval
This work was conducted with the approval of the Animal Ethics Subcommittee of the Philadelphia VA Medical Center, project number 01251.
This study was funded by a Department of Veterans Affairs Merit Grant (I01RX000211) and supported by the Penn Center for Musculoskeletal Disorders.
- Freemont AJ: The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain. Rheumatology 2009,48(1):5–10. 10.1093/rheumatology/ken396PubMedView ArticleGoogle Scholar
- Smith LJ, Nerurkar NL, Choi KS, Harfe BD, Elliott DM: Degeneration and regeneration of the intervertebral disc: lessons from development. Dis Model Mech 2011,4(1):31–41. 10.1242/dmm.006403PubMedView ArticlePubMed CentralGoogle Scholar
- Adams MA, McNally DS, Dolan P: 'Stress' distributions inside intervertebral discs. The effects of age and degeneration. J Bone Joint Surg (Br) 1996,78(6):965–972. 10.1302/0301-620X78B6.1287View ArticleGoogle Scholar
- Le Maitre CL, Freemont AJ, Hoyland JA: The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther 2005,7(4):R732–745. 10.1186/ar1732PubMedView ArticlePubMed CentralGoogle Scholar
- Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA: Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans 2007,35(Pt 4):652–655.PubMedView ArticleGoogle Scholar
- Arend WP: Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991,88(5):1445–1451. 10.1172/JCI115453PubMedView ArticlePubMed CentralGoogle Scholar
- Smith LJ, Chiaro JA, Nerurkar NL, Cortes DH, Horava SD, Hebela NM, Mauck RL, Dodge GR, Elliott DM: Nucleus pulposus cells synthesize a functional extracellular matrix and respond to inflammatory cytokine treatment following long term agarose culture. Eur Cells Mater 2011,20(22):291–301.Google Scholar
- Gorth DJ, Mauck RL, Chiaro JA, Mohanraj B, Hebela NM, Dodge GR, Elliott DM, Smith LJ: IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1beta-mediated degradation of nucleus pulposus in vitro. Arthritis Res Ther 2012,14(4):R179. 10.1186/ar3932PubMedView ArticlePubMed CentralGoogle Scholar
- Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R: Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 1991,8(6):713–720. 10.1023/A:1015841715384PubMedView ArticleGoogle Scholar
- Pisal DS, Kosloski MP, Balu-Iyer SV: Delivery of therapeutic proteins. J Pharm Sci 2010,99(6):2557–2575. 10.1002/jps.22054PubMedView ArticlePubMed CentralGoogle Scholar
- Farndale RW, Buttle DJ, Barrett AJ: Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986,883(2):173–177. 10.1016/0304-4165(86)90306-5PubMedView ArticleGoogle Scholar
- Mertens M, Singh JA: Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009,36(6):1118–1125. 10.3899/jrheum.090074PubMedView ArticleGoogle Scholar
- Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE: Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009,61(3):344–352. 10.1002/art.24096PubMedView ArticleGoogle Scholar
- Le Maitre CL, Hoyland JA, Freemont AJ: Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study. Arthritis Res Ther 2007,9(4):R83. 10.1186/ar2282PubMedView ArticlePubMed CentralGoogle Scholar
- Phillips KL, Jordan-Mahy N, Nicklin MJ, Le Maitre CL: Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration. Ann Rheum Dis 2013,72(11):1860–1867. 10.1136/annrheumdis-2012-202266PubMedView ArticleGoogle Scholar
- Prescribing Information: Kineret (Anakinra). Thousand Oaks, CA, ᅟ; 2009.
- Felka T, Schafer R, Schewe B, Benz K, Aicher WK: Hypoxia reduces the inhibitory effect of IL-1beta on chondrogenic differentiation of FCS-free expanded MSC. Osteoarthritis Cartilage 2009,17(10):1368–1376. 10.1016/j.joca.2009.04.023PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.